View Older Stories View More Recent Stories

Nov 13, 2015 08:00AM AbbVie Submits IMBRUVICA® (ibrutinib) Phase III Combination Data to U.S. FDA
Nov 5, 2015 10:30AM AbbVie's Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers
Nov 5, 2015 08:00AM AbbVie to Present at Jefferies Autumn 2015 Global Healthcare Conference in London
Nov 3, 2015 08:00AM AbbVie's Leadership and Innovation in Immunology Showcased at the American College of Rheumatology Annual Meeting with More Than 40 Abstracts on HUMIRA® (adalimumab) and Investigational Medicines Acr
Nov 2, 2015 12:04PM AbbVie to Present at Credit Suisse 24th Annual Healthcare Conference
Oct 30, 2015 06:55AM AbbVie Reports Third-Quarter 2015 Financial Results
Oct 30, 2015 06:54AM AbbVie Outlines Long-Term Strategic and Financial Objectives; Company Positioned for Strong Performance
Oct 28, 2015 08:30AM IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent
Oct 22, 2015 06:21PM AbbVie Updates U.S. Labels for VIEKIRA PAK® and TECHNIVIE™
Oct 8, 2015 06:15AM Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECT
Oct 6, 2015 08:05AM AbbVie to Host Third-Quarter Earnings Conference Call
Oct 5, 2015 09:00AM AbbVie Demonstrates Leadership in Dermatology with 26 Abstracts at the European Academy of Dermatology and Venereology Congress
Oct 1, 2015 01:02PM AbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and Ongoing Clinical Development Program at The
Sep 28, 2015 02:00AM AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
Sep 25, 2015 07:13AM AbbVie to Advance Once-Daily ABT-494 to Phase 3 in Rheumatoid Arthritis by Year-End
Sep 25, 2015 07:12AM AbbVie's ABT-494 Meets Primary Endpoint in Two Phase 2 Studies in Rheumatoid Arthritis
Sep 16, 2015 09:00AM AbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids
Sep 14, 2015 08:30AM AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment-Naive Chronic Lymphocytic Leukemia
Sep 11, 2015 01:45PM AbbVie Declares Quarterly Dividend
Sep 10, 2015 05:13PM AbbVie to Present at 2015 Morgan Stanley Global Healthcare Conference
Sep 10, 2015 03:43PM AbbVie's HUMIRA® (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa
Sep 9, 2015 08:00AM Cast Your Vote for the 2015 Thriving Undergraduate and Graduate Scholars to Help Grant Two $20,500 AbbVie Scholarships to Students with Cystic Fibrosis
Sep 1, 2015 07:30AM U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or Mo
Aug 12, 2015 08:30AM Phase 2 Study of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion Meets Primary Endpoint
Jul 27, 2015 07:00AM European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Recei
Jul 24, 2015 02:00PM TECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S.
Jul 24, 2015 07:53AM AbbVie Reports Second-Quarter 2015 Financial Results
Jul 17, 2015 08:01AM C2N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy
Jul 10, 2015 07:10AM IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenstrom's Macroglobulinemia in Europe
Jul 2, 2015 08:00AM AbbVie to Host Second-Quarter Earnings Conference Call
Jun 24, 2015 06:00AM AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis
Jun 18, 2015 05:01PM AbbVie Declares Quarterly Dividend
Jun 12, 2015 09:00AM AbbVie to Present Data from Studies of DUOPA® (carbidopa and levodopa) Enteral Suspension in Advanced Parkinson's Disease During the International Congress of Parkinson's Disease and Movement Disorde
Jun 12, 2015 02:30AM Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Jun 8, 2015 08:00AM AbbVie Mobilizes 3,100 Employees for Week of Service Projects to Transform Schools and Communities Globally
Jun 8, 2015 08:00AM AbbVie to Present Data from Studies of the Company's Oncology Pipeline at the 20th European Hematology Association Annual Congress
Jun 5, 2015 04:00PM AbbVie to Present at Goldman Sachs 36th Annual Global Healthcare Conference
Jun 4, 2015 07:00AM AbbVie's Research in Immunology to be Featured at the European League Against Rheumatism Annual Congress (EULAR) 2015
Jun 2, 2015 10:45AM Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from ELOQUENT-2 Trial Publishe
Jun 1, 2015 12:22PM AbbVie to Present at Jefferies 2015 Healthcare Conference
Jun 1, 2015 08:00AM AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting
May 31, 2015 08:00AM AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting
May 26, 2015 07:00PM AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis
May 26, 2015 08:30AM AbbVie Completes Acquisition of Pharmacyclics
May 22, 2015 08:00AM AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of Pharmacyclics
May 21, 2015 08:00AM AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics
May 15, 2015 04:43PM AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
May 15, 2015 09:44AM AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativa (HS)
May 13, 2015 08:15AM AbbVie to Present at UBS Global Healthcare Conference
May 12, 2015 08:02AM AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive Disease Week® (DDW) 2015
View More Recent Stories View Older Stories